PurMinds NeuroPharma has completed its acquisition of a novel chemical entity called SW-200, which is a selective histone deacetylase 6 (HDAC6) inhibitor. HDAC6 inhibitors have the potential to enhance axonal transport in neurons, making them a novel class of therapeutics for neurodegenerative disorders. PurMinds aims to develop an HDAC6 inhibitor for Charcot-Marie-Tooth Disease and other neurological disorders like Alzheimer’s, Parkinson’s, and multiple sclerosis, which share axonal dysfunction as a pathological mechanism. The NCE was invented by Dr. Alan Kozikowski and holds promise for addressing conditions currently lacking a cure.
PurMinds NeuroPharma (“PurMinds” or the “Company”), a neuroscience company with a robust clinical pipeline combining small molecules, psychedelic compounds and other modalities, pursuing breakthrough therapeutic solutions for neurological disorders hallmarked by neurodegeneration, today announced completion of acquisition of a small molecule novel chemical entity (NCE) known as SW-200, a non-hydroxamic acid that shows superior histone deacetylase 6 (HDAC6) selectivity.
Drugs that inhibit the molecular target HDAC6 are a novel class of therapeutics that are able to functionally enhance the axonal transport of nutrients, growth factors and neurotransmitters in neurons. Encouraged by scientific studies that have shown efficacy in rodent models of neurodegenerative disorders, PurMinds NeuroPharma anticipates the successful development of an HDAC6 inhibitor for Charcot-Marie Tooth Disease (CMT) – a progressive neurodegenerative disorder, which causes disabling deficits in nerve function affecting 1 in 2500 people with no current cure. In addition, due to the shared pathological mechanism of axonal dysfunction, our HDAC6i may be used to treat a host of other neurological disorders including Amyotrophic Lateral Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis and Chemotherapy-Induced Cognitive Impairment.
The NCE was invented by Dr. Alan Kozikowski, a Global leader in medicinal chemistry designing NCEs for oncology and neuroscience, and is known for his research on 5-HT receptors, HDAC inhibitors and GSK-3 inhibitors. Dr. Kozikowski is currently sitting on PurMinds Scientific Advisory Board.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“HDAC6 inhibition represents an innovative therapeutic target to address a range of neurological conditions currently without a cure. HDAC6 inhibitors are capable of outperforming many existing therapies by restoring and preventing the root cause of neuron deterioration in progressive neurodegenerative diseases, as opposed to merely treating symptoms,” said PurMinds’ Chief Innovation Officer, Dr. Amy Reichelt.
Source: BioSpace